{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pan SD"],"funding":["Swiss National Science Foundation"],"pagination":["588195"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7674855"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["<h4>Background</h4>Microglia initiates and sustains the inflammatory reaction that drives the pathogenesis of pneumococcal meningitis. The expression of the G-protein cannabinoid receptor type 2 (CB2) in the brain is low, but is upregulated in glial cells during infection. Its activation down-regulates pro-inflammatory processes, driving microglia towards an anti-inflammatory phenotype. CB2 agonists are therefore therapeutic candidates in inflammatory conditions like pneumococcal meningitis. We evaluated the effects of JWH-133, a specific CB2 agonist on microglial cells, inflammation, and damage driven by <i>S. pneumoniae</i> <i>in vitro</i> and in experimental pneumococcal meningitis.<h4>Materials/methods</h4>Primary mixed glial cultures were stimulated with live or heat-inactivated <i>S."],"journal":["Frontiers in cellular and infection microbiology"],"pubmed_title":["Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis."],"pmcid":["PMC7674855"],"funding_grant_id":["189136"],"pubmed_authors":["Leib SL","Grandgirard D","Pan SD"],"additional_accession":[]},"is_claimable":false,"name":"Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis.","description":"<h4>Background</h4>Microglia initiates and sustains the inflammatory reaction that drives the pathogenesis of pneumococcal meningitis. The expression of the G-protein cannabinoid receptor type 2 (CB2) in the brain is low, but is upregulated in glial cells during infection. Its activation down-regulates pro-inflammatory processes, driving microglia towards an anti-inflammatory phenotype. CB2 agonists are therefore therapeutic candidates in inflammatory conditions like pneumococcal meningitis. We evaluated the effects of JWH-133, a specific CB2 agonist on microglial cells, inflammation, and damage driven by <i>S. pneumoniae</i> <i>in vitro</i> and in experimental pneumococcal meningitis.<h4>Materials/methods</h4>Primary mixed glial cultures were stimulated with live or heat-inactivated <i>S.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020","modification":"2025-04-26T04:19:15.667Z","creation":"2021-02-20T02:46:22Z"},"accession":"S-EPMC7674855","cross_references":{"pubmed":["33251159"],"doi":["10.3389/fcimb.2020.588195"]}}